Keith A. Goldan - 04 Feb 2026 Form 4 Insider Report for Syndax Pharmaceuticals Inc (SNDX)

Reporting relationship: Chief Financial Officer
Issuer ticker: SNDX
Reported as of: 04 Feb 2026
Net transaction value: +$2,378,146
SEC form: 4
Accepted by SEC: 06 Feb 2026, 17:53:43 UTC
Prior SEC filing: 01 Dec 2025
Next SEC filing: 10 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Michael A. Metzger, Attorney-in-Fact

Key filing fact

Keith A. Goldan filed Form 4 for Syndax Pharmaceuticals Inc (SNDX) on 06 Feb 2026.

Key facts

This page summarizes Keith A. Goldan's Form 4 filing for Syndax Pharmaceuticals Inc (SNDX).
5 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 06 Feb 2026, 17:53.

Change

Previous filing in this sequence was filed on 01 Dec 2025.
Current net transaction value: +$2,378,146.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001495411 Primary reporting owner

Goldan Keith A.

Relationship: Chief Financial Officer
Address: 730 THIRD AVENUE, FLOOR 9, NEW YORK
Signature: /s/ Michael A. Metzger, Attorney-in-Fact
Signature date: 06 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SNDX transaction

Common Stock

Other

Transaction value: $10,337
Shares: +1,219
Change %: +1.3%
Price: $8.48
Shares after: 93,671
Date: 30 Jan 2026
Ownership: Direct
Footnotes: F1

SNDX transaction

Common Stock

Award

Transaction value: $0
Shares: +21,500
Change %: +23%
Price: $0.000000
Shares after: 115,171
Date: 04 Feb 2026
Ownership: Direct
Footnotes: F2

SNDX transaction

Common Stock

Award

Transaction value: $0
Shares: +30,750
Change %: +27%
Price: $0.000000
Shares after: 145,921
Date: 04 Feb 2026
Ownership: Direct
Footnotes: F3

SNDX transaction

Common Stock

Sale

Transaction value: $42,931
Shares: -2,082
Change %: -1.4%
Price: $20.62
Shares after: 143,839
Date: 06 Feb 2026
Ownership: Direct
Footnotes: F4

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SNDX transaction Derivative

Stock Options (Right to buy)

Award

Transaction value: $2,410,740
Shares: +118,000
Change %
Price: $20.43
Shares after: 118,000
Date: 04 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 118,000
Exercise price: $20.43
Footnotes: F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

The Reporting Person is voluntarily filing this Form 4 to report the acquisition of 1,219 shares by the Reporting Person on 1/30/2026 pursuant to the Issuer's Employee Stock Purchase Plan.

Footnote F2

Award of restricted stock units ("RSUs"), representing the right to receive one share of Common Stock for each RSU. One third (1/3rd) of the shares of Common Stock subject to such RSU shall vest annually on the anniversary of the Vesting Commencement Date, during the Reporting Person's continued service as an employee, consultant, director or officer of the Company over the three (3) years following the date of grant, until all of the shares subject to such RSU are fully vested.

Footnote F3

Award of RSUs, representing the right to receive one share of Common Stock for each RSU. The number of shares of Common Stock acquired upon vesting of the RSUs is contingent upon the achievement of pre-established performance metrics, as approved by the Company's Compensation Committee, subject to the Reporting Person's continued service as an employee, consultant, director or officer of the Company.

Footnote F4

Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units.

Footnote F5

1/48th of the shares subject to the option shall vest monthly over a four-year period.